An observational study in Renal Cell Cancer Metastatic, sponsored by Zhe Chen. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Zhe Chen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carcinoma, Renal Cell with a site in Japan — 6 open to participants now, 17 under way, 6 of them phase 3. Carcinoma, Renal Cell · Japan.
Among the 71 studies in Carcinoma, Renal Cell with a site in Japan, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 13 of the 16 other live ones, and was the 70th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →6 of the 71 studies in Carcinoma, Renal Cell with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Argentina and 17 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Australia and 3 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Australia and 1 more country
Ages 18+
Bristol-Myers Squibb · Sites in Japan, United States, Australia and 5 more countries
Ages 18+
Calico Life Sciences LLC · Sites in Japan, United States, France and 3 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 17 · Phase 3 22
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 145 is close to the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 185 across the 60 interventional studies, 286 across the 11 observational. Of the 51 that completed or were terminated, 32 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 71 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhe Chen as lead sponsor.
Zhe Chen has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Renal Cell with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04707248Daiichi SankyoA Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | 2026-12-30 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
| NCT07227415PfizerSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | 2027-11-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 71 studies in Carcinoma, Renal Cell with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter observational study is to elucidate the clinical and immunological characteristics of the abscopal effect in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitors (ICI) combined with image-guided ultra-hypofractionated radiotherapy (IGU).
The main questions this study aims to answer are:
What is the abscopal response rate (ARR) at one year after IGU in patients continuing ICI treatment?
What clinical and immunological factors are associated with the occurrence and timing of the abscopal effect?
Participants are patients with mRCC who have experienced immune-confirmed stable or progressive disease during ICI therapy and are scheduled to receive IGU to a selected lesion. Researchers will observe tumor responses at irradiated and non-irradiated sites using standard imaging (CT/MRI) and collect clinical and laboratory data at baseline, 3, 6, 9, and 12 months after IGU. Optional exploratory blood samples will be obtained for cytokine analysis (e.g., IFN-β, IFN-γ, TNF-α, IL-6).
The primary outcome is the abscopal response rate (ARR) at one year after IGU. Secondary outcomes include tumor shrinkage rate of irradiated and non-irradiated lesions, 1-year overall survival, disease-specific survival, and progression-free survival.
This study seeks to establish a foundation for developing combined immunotherapy and ultra-hypofractionated radiotherapy strategies for metastatic renal cell carcinoma.
*This study is led by Prof. Hiroshi Onishi (University of Yamanashi). The registry entry is managed by Dr. Zhe Chen on behalf of the study group.
Renal cell carcinoma (RCC) is a highly immunogenic tumor that exhibits intrinsic resistance to cytotoxic chemotherapy and conventional radiotherapy. With the introduction of immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, the survival outcomes of patients with metastatic RCC (mRCC) have markedly improved. However, disease control remains suboptimal in a considerable fraction of patients who experience immune-confirmed stable disease or progression despite continued ICI therapy. For such patients, locoregional treatment targeting oligoprogressive lesions may modulate tumor immunogenicity and enhance systemic immune responses.
Radiation therapy, particularly when administered in large doses per fraction (ablative or ultra-hypofractionated schedules), can induce systemic antitumor effects mediated by immune activation, known as the abscopal effect. This effect refers to regression of non-irradiated metastatic lesions following local irradiation, thought to arise from radiation-induced antigen release and subsequent immune activation. Although multiple case reports and small series have described this phenomenon, the true frequency, biological basis, and predictive factors of the abscopal effect in mRCC remain poorly defined.
The AURICRE study (Observational Study on the Abscopal Effect by Ultra-Hypofractionated Radiation Therapy in Combination with Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma) is a multicenter prospective observational registry initiated by the Department of Imaging-Integrative Therapeutic Radiology, University of Yamanashi. The study is designed to clarify the incidence, timing, and clinical-immunological correlates of the abscopal effect in patients with mRCC treated with ICIs who undergo ultra-hypofractionated image-guided radiotherapy (IGU) to a metastatic lesion. This investigation will also provide a foundation for the rational development of future ICI-radiotherapy combination strategies.
Study Objectives
Primary Objective To elucidate the clinical and immunological characteristics associated with the abscopal effect in mRCC patients receiving ICIs and to determine the abscopal response rate (ARR) at one year after IGU.
Secondary Objectives
To evaluate:
The tumor shrinkage rate of irradiated and non-irradiated lesions at each follow-up interval
One-year overall survival (OS)
One-year disease-specific survival (DSS)
One-year progression-free survival (PFS)
Exploratory Objectives To explore cytokine dynamics and immune biomarkers (e.g., IFN-β, IFN-γ, TNF-α, IL-6) that may predict or accompany the abscopal effect.
Study Design
This study is a prospective, multicenter, observational design conducted from 2025 to 2028. Eligible patients are adults with histologically confirmed metastatic RCC who have received ICIs and demonstrated immune-confirmed stable disease or progression. Participants must be candidates for ultra-hypofractionated radiotherapy to at least one metastatic lesion according to clinical judgment. There is no randomization or additional therapeutic intervention mandated by the protocol beyond standard care.
Treatment and Assessment Schedule
IGU will be performed using stereotactic or equivalent ultra-hypofractionated techniques (typically 24-30 Gy in 1-3 fractions) targeting a single or limited number of lesions, with attention to organ-at-risk constraints. The selection of the irradiation site and dose prescription will follow institutional standards.
Participants will continue ICI therapy at the discretion of their treating oncologist. Imaging assessments (CT or MRI) will be performed at baseline, and at 3, 6, 9, and 12 months post-IGU to evaluate responses in irradiated and non-irradiated lesions based on RECIST 1.1 criteria and radiological review. Optional exploratory blood sampling for cytokine analysis will be performed at corresponding time points. Clinical status, laboratory parameters, and toxicity will be documented throughout the observation period.
Endpoints and Data Collection
Primary Endpoint
Abscopal response rate (ARR) at one year after IGU, defined as a ≥30 % reduction in the sum of diameters of non-irradiated target lesions without new lesion appearance.
Secondary Endpoints
Tumor shrinkage rates of irradiated and non-irradiated lesions
1-year OS, DSS, and PFS
Patterns and timing of the abscopal response
Exploratory Endpoints
Temporal changes in serum cytokine levels
Correlation between immune parameters and clinical response
Data will be collected using an electronic data capture (EDC) system. Each participating site will record baseline demographics, disease characteristics, treatment details, and follow-up results in standardized formats to ensure uniformity across institutions.
Sample Size and Statistical Considerations
The target accrual is approximately 50-60 patients based on feasibility across participating centers. Statistical analyses will include logistic regression to assess predictors of the abscopal response, incorporating variables such as age, sex, number of lesions, prior lines of therapy, and ICI type. Receiver operating characteristic (ROC) curve analysis will determine optimal cut-off values for significant predictors. Survival outcomes will be estimated using the Kaplan-Meier method. Missing data will be analyzed for pattern and mechanism; if imputation is warranted, multiple imputation or appropriate statistical techniques will be employed.
Ethical Considerations and Oversight
This study is conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Japan). The protocol and informed consent documents have been approved by the University of Yamanashi Ethics Committee (approval date: October 27, 2025). Each participating institution will obtain local approval where required. Written informed consent will be obtained from all participants prior to enrollment.
Scientific and Clinical Significance
The AURICRE study will be among the first systematic multicenter efforts to characterize the abscopal effect in mRCC under contemporary immunotherapy settings. By integrating clinical outcomes, radiologic responses, and exploratory immune profiling, this study will clarify real-world frequency and predictors of systemic immune activation triggered by ultra-hypofractionated radiotherapy. The findings are expected to provide a mechanistic and clinical rationale for future prospective trials combining radiotherapy and immunotherapy, ultimately contributing to the advancement of immune-radiotherapeutic strategies for renal cell carcinoma.
Adult patients (≥18 years) with histologically confirmed metastatic renal cell carcinoma (mRCC) who are receiving ICIs and are candidates for IGU to one or more metastatic lesions. Eligible patients must have immune-confirmed stable disease or progression during ongoing ICI therapy. Enrollment will include patients treated at participating centers of the AURICRE multicenter registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with active double cancers (synchronous double cancers or metachronous double cancers with a disease-free interval within 2 years).
However, carcinoma in situ or intramucosal carcinoma considered cured by treatment, and the following tumors even if within 2 years of disease-free interval are not excluded: gastric cancer stage 0-II (UICC), prostate cancer stage I-III, colorectal cancer stage 0-II, esophageal cancer stage 0-I, breast cancer stage 0-II, endometrial cancer stage I-II, cervical cancer stage 0-II, and thyroid cancer stage I-III. In addition, any cancer with a disease-free interval greater than 2 years is not excluded regardless of stage.
Patients with serious comorbidities, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes patients with histologically confirmed mRCC who are receiving ICIs and undergo IGU to a selected metastatic lesion as part of their standard clinical care. Patients are followed prospectively for one year to evaluate abscopal responses, survival outcomes, and immune-related biomarkers.
Abscopal Response Rate (ARR) at 1 Year After IGU
The proportion of patients showing an abscopal response, defined as a ≥30% reduction in the sum of diameters of non-irradiated target lesions without new lesion appearance, evaluated according to RECIST 1.1 criteria. Tumor response will be assessed by radiological imaging (CT or MRI) at each follow-up visit and confirmed by central review.
Time frame: 12 months after image-guided ultra-hypofractionated radiotherapy (IGU)
Tumor Shrinkage Rate of Irradiated and Non-Irradiated Lesions
The percentage change in the sum of diameters of irradiated and non-irradiated lesions from baseline, assessed by RECIST 1.1 at each follow-up (3, 6, 9, and 12 months).
Time frame: Baseline to 12 months after IGU
One-Year Overall Survival (OS)
Overall survival defined as the time from initiation of IGU to death from any cause. Patients alive at the end of follow-up will be censored at the date of last contact.
Time frame: 12 months after IGU
One-Year Disease-Specific Survival (DSS)
Disease-specific survival defined as the time from IGU to death due to renal cell carcinoma. Deaths from other causes will be censored at the date of death.
Time frame: 12 months after IGU
One-Year Progression-Free Survival (PFS)
Progression-free survival defined as the time from IGU to disease progression or death, whichever occurs first, based on RECIST 1.1 criteria.
Time frame: 12 months after IGU
Temporal Changes and Correlation of Serum Cytokine Profiles With Abscopal Response
Quantitative changes in circulating cytokines (IFN-β, IFN-γ, TNF-α, IL-6) measured by enzyme-linked immunosorbent assay (ELISA) at baseline and 3 and 12 months after IGU. Statistical correlations between cytokine dynamics and abscopal response rate will be analyzed using logistic regression and receiver operating characteristic (ROC) analysis.
Time frame: Baseline to 12 months after IGU
Plan to share: No — Individual participant data (IPD) will not be shared because the study involves identifiable clinical information collected in a multicenter observational registry. Data sharing is restricted by institutional and ethical regulations at participating sites, and access is limited to the study investigators for predefined analyses.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.
Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 28 months is below that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.